Alpenglow Biosciences and CorePlus partner to bring 3D spatial biology to clinical R&D

Photo/Shutterstock
tissue cells

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*
This field is for validation purposes and should be left unchanged.

Spatial biology company Alpenglow Biosciences is partnering with CorePlus, a high complexity CLIA-certified clinical and anatomic pathology laboratory, to digitize and analyze tissues in 3D to deliver novel spatial biology insights and accelerate drug development. 

As part of the partnership, CorePlus will invest in Alpenglow and receive access to Alpenglow’s 3Deep Imager, a hybrid open top lightsheet imaging platform.

Mariano de Socarraz, founder and CEO at CorePlus, said: “We continue our quest for innovation and precision diagnostics. We are excited to partner with Alpenglow to incorporate their proprietary 3D spatial biology platform. Having been the first laboratory in the Americas to operationalize AI in prostate cancer, our team sees the value in advancing the transformation in pathology to incorporate 3D technology.”

Leveraging imaging, data processing and analysis, Alpenglow’s 3Deep Imager acts as a flatbed scanner for tissue and generates up to 250 times more data than traditional slide-based pathology. The company said this yields much richer datasets and insights used for artificial intelligence and machine learning. Alpenglow’s solution for whole tissue imaging is non-destructive, slide-free and direct to digital.

Nicholas Reder, MPH and CEO at Alpenglow, said: “We are thrilled to partner with CorePlus and bring our 3D spatial biology platform to an innovative laboratory where our automated high-throughput imaging and data processing solutions will create rich datasets to identify 3D biomarkers using machine learning and unlock exciting applications for our pharma partners.”

Alpenglow and CorePlus aim to leverage 3D datasets to identify 3D biomarkers which could be used to improve patient selection for clinical trials, thereby reducing trial size and accelerating clinical development.

About Alpenglow Biosciences

Alpenglow Biosciences is a privately held, venture-backed company focused on accelerating drug development and improving clinical diagnostics with AI-enabled 3D imaging technology. It partners with pharmaceutical companies to bring better therapeutics to market faster through greater understanding of mechanism of action, efficacy and toxicology, and patient trial enrolment. 

About CorePlus

CorePlus is a high complexity CLIA certified laboratory with facilities in the U.S. and Ponce, Puerto Rico. The CorePlus team of pathologists has become the first in the Americas to implement primary digital pathology-based 3D imaging protocols in a CLIA-setting utilizing Alpenglow’s 3Deep Imager solution.

Explore other topics: